A concentration calculation describes what should be in a solution under its assumptions. A laboratory measurement asks what the analytical method actually detects. When those numbers disagree, the container deserves attention alongside the instrument and the calculation.
One possible explanation is adsorption: molecules attaching to a surface, such as a sample tube or vial wall. This differs from absorption into a material. A handling step that looks routine can therefore become a variable in an analytical experiment.
The useful question is specific: has recovery been evaluated for this molecule, in this container, under this method’s conditions?
What the experiments show
In a peer-reviewed laboratory study published on 1 May 2015, Kristensen and colleagues used analytical HPLC to examine three cationic peptides: mastoparan X, melittin and magainin 2. Recovery depended on container type and experimental conditions. Successive transfers through ordinary glass or polypropylene containers produced substantial losses in the tested systems; Protein LoBind tubes reduced losses under the conditions investigated. [1]
These were three particular peptides, not a test of every research peptide. The findings do not provide a loss percentage for an unrelated molecule, commercial vial or formulation.
A second analytical study, first published on 7 October 2020 and appearing in a 2021 journal issue, came from researchers at the Atlantic Cancer Research Institute and Mount Allison University in New Brunswick. Murphy and colleagues compared conventional and low-bind tubes and LC vials using the peptide Vn96 and two intact proteins. Low-bind containers improved the peptide’s analytical response, while the proteins required additional method-specific measures to obtain linear calibration. [2]
The contrast matters: an improvement for one analyte does not validate a handling approach for another. This study also did not address adsorption throughout every instrument component.
Three questions to keep separate
| Question | What it tells you | What it leaves open |
|---|---|---|
| What concentration was calculated? | The result of the stated mass and final-volume inputs | Whether those inputs describe the recoverable material |
| What amount was recovered or detected? | A result obtained through a particular analytical workflow | Whether loss, interference or other method effects explain a difference |
| Why did results differ? | A conclusion requiring controls and investigation | A weak signal alone does not identify its cause |
Adsorption is a possible explanation, not an automatic diagnosis. An unexpected signal should trigger a documented investigation rather than a conclusion about the original material.
A record that makes handling visible
For a laboratory team comparing results, “stored in a tube” is too vague. The following record is an editorial checklist, not a validated analytical protocol:
| Field | Record |
|---|---|
| Material | Sample identifier, molecule and available lot information |
| Containers | Manufacturer, product code, material and stated surface treatment |
| Solution | Composition, stated concentration and final volume |
| Contact history | Transfers, contact times and relevant temperature records |
| Analysis | Method version, calibration approach and measurement units |
| Controls | Applicable blanks and recovery checks defined by the laboratory |
| Result | Observations, uncertainty and unresolved explanations |
Consistent records help reveal differences between workflows. They do not eliminate the need for a fit-for-purpose method. A label such as “low-bind” is a reason to investigate suitability, not a substitute for evidence under the actual assay conditions.
Before changing a workflow, ask the analytical laboratory whether the proposed container or handling change requires a recovery comparison or further validation. Solvent and additive choices belong to that method assessment; this article supplies no preparation recipe.
The Canadian documentation context
Health Canada’s Guide to validation , drugs and supporting activities, published 29 June 2021, calls for analytical validation studies to follow an approved protocol and reach a clear conclusion in a report. Its scope is drug operations; it is cited here as a documentation reference, not a declaration that BLOOM or a research laboratory meets its requirements. [3]
Analytical evidence and Canadian product authorization remain separate questions. Health Canada’s 9 April 2026 peptide advisory explicitly states that research-use labelling does not exempt products from regulatory requirements. A COA or recovery experiment likewise does not establish marketing authorization. [4]
For laboratory interpretation, the next step is a precise question to the laboratory: what evidence shows that this workflow measures this analyte reliably?